TFRC and stroke disorder: Compared to the control group, the expression levels of TFR1, HMOX1 and SLC3A2 in PC12 cells treated with OGD/R were significantly increased in the model group; compared to the model group, the expression of TFR1, HMOX1 and SLC3A2 in cells treated with 6.25 μM, 12.5 μM and 25 μM Iristectorin B decreased 24 h later, and the expression of Edaravone in the positive group also decreased significantly (Figure 12), which indicates that Iristectorin B can reduce the expression of TFR1, HMOX1 and SLC3A2 in OGD/R cells, thereby playing a role in protecting stroke by inhibiting ferroptosis.